Piper Sandler Reiterates Overweight Rating for Moderna (NASDAQ:MRNA)
Moderna (NASDAQ:MRNA – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Sandler in a research report issued on Friday, Benzinga reports. They currently have a $157.00 target price on the stock, down from their previous target price of $214.00. Piper Sandler’s price objective would suggest a potential upside […]
More Stories
Iran Hasn’t Exported Crude Oil in 28 Days Amid US Blockade: Maritime Intelligence Company
By Victoria Friedman The Iranian regime has not been able to export any crude oil for nearly a month amid...
CIA Analysts Believed COVID-19 Came From Lab, Leaders Buried Assessments: Whistleblower
By Zachary Stieber CIA experts believed COVID-19 likely came from a laboratory in China, but leaders in the agency changed...
EBay Turns Down GameStop’s $55.5 Billion Takeover Proposal
By Andrew Moran EBay has turned down videogame retailer GameStop’s $55.5 billion takeover proposal. The online marketplace, in a May...
Trump Nominates Lake, Mastriano to Diplomatic Posts
By Kimberly Hayek President Donald Trump on Monday announced a slew of nominations sent to the U.S. Senate, including two...
Treasury Department Alerts US Banks to Suspected Iranian Money Laundering Efforts
By Victoria Friedman The U.S. Treasury Department’s Financial Crimes Enforcement Network (FinCEN) on May 11 issued an alert to financial...
Gas Prices Lift US Annual Inflation Rate to 3.8 Percent Highest Since May 2023
By Andrew Moran Consumer prices accelerated for the second straight month in April as the war in Iran added to...